{"id":"NCT05275400","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin","officialTitle":"A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-03-08","primaryCompletion":"2024-05-15","completion":"2024-05-15","firstPosted":"2022-03-11","resultsPosted":"2025-06-03","lastUpdate":"2025-06-03"},"enrollment":986,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Insulin Efsitora Alfa","otherNames":["LY3209590 and Basal Insulin-FC"]},{"type":"DRUG","name":"Insulin Degludec","otherNames":[]}],"arms":[{"label":"500 U/mL - Insulin Efsitora","type":"EXPERIMENTAL"},{"label":"100 U/mL - Insulin Degludec","type":"ACTIVE_COMPARATOR"}],"summary":"The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes that have already been treated with basal insulin. The study consists of a 3-week screening/lead-in period, a 78-week treatment period and a 5-week safety follow-up period. The study will last up to 86 weeks.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority]","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"500 U/mL - Insulin Efsitora","deltaMin":-0.81,"sd":0.0302},{"arm":"100 U/mL - Insulin Degludec","deltaMin":-0.72,"sd":0.0424}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":127,"countries":["United States","Argentina","Hungary","Japan","Poland","Puerto Rico","Slovakia","South Korea","Spain","Taiwan"]},"refs":{"pmids":["40562047"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/2r9JxzEnerVifDDkc8VETS"]},"adverseEventsSummary":{"seriousAny":{"events":103,"n":655},"commonTop":["Covid-19","Nasopharyngitis","Dose calculation error","Upper respiratory tract infection","Diarrhoea"]}}